ArticleThe Journal of antimicrobial chemotherapy2025
Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study.
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolutionary digital twin framework for optimal aminoglycoside dosing in neonates with suspected sepsis.NPJ digital medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectivesEarly-onset sepsis (EOS) poses a significant morbidity and mortality risk in neonates, for which early diagnosis and adequate antibiotic therapy is crucial. Amoxicillin and benzylpenicillin combined with aminoglycosides are often prescribed empirically for neonatal EOS but optimal dosing regimens are lacking. To evaluate the pharmacokinetics (PK), PTA and toxicity of amoxicillin and benzylpenicillin in (pre)term neonates with EOS, and define optimal dosing regimens.
methodsOne hundred forty-five neonates [gestational age (GA): 24-42 weeks] with EOS treated with intravenous amoxicillin or benzylpenicillin, dosed as per the Dutch Pediatric Formulary (DPF), were included. Amoxicillin and benzylpenicillin were quantified in left-over samples during the first 48 h of life. First, the performance of nine paediatric amoxicillin and benzylpenicillin population PK models was evaluated. Second, the most appropriate models were used for simulation-based PTA and toxicity analyses, evaluating eight international neonatal dosing regimens. Third, simulation-based dose optimization was conducted.
resultsThe Bijleveld (amoxicillin) and Padari (benzylpenicillin) models adequately described the obtained PK data (N = 252). For amoxicillin, all regimens showed >90% PTA up to 100%fT > MIC but displayed GA-dependent toxicity potential (concentrations >110 mg/L), the DPF regimen excepted. By contrast, all benzylpenicillin regimens showed suboptimal PTA, often accompanied with GA-dependent toxicity potential (concentrations >50 mg/L). Simulations indicated GA-based intermittent dosing or continuous infusion as options to further optimize benzylpenicillin therapy.
conclusions(Pre)term neonates with EOS can be adequately treated with amoxicillin dosed as per the DPF regimen. By contrast, further optimization is warranted for benzylpenicillin, for which GA-based intermittent dosing or continuous infusion pose potential alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.